This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatine, M. S. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Sabatine, M. S. Articles by Braunwald, E.

(Circulation. 2001;104:2759.)
© 2001 American Heart Association, Inc.

Editorial

Will Diabetes Save the Platelet Blockers?

Marc S. Sabatine, MD; Eugene Braunwald, MD

From the TIMI Study Group and Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Marc S. Sabatine, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. E-mail msabatine@partners.org

Key Words: Editorials • diabetes mellitus • coronary disease • platelets • glycoproteins

More than 30 000 patients have been enrolled in trials assessing the efficacy of glycoprotein (GP) IIb/IIIa inhibitors in unstable angina (UA) or non–ST-segment elevation MI (NSTEMI). The initial trials demonstrated that the use of a GP IIb/IIIa inhibitor resulted in a significant decrease in the rate of death or nonfatal myocardial infarction.^1,2 More recently, however, the GP IIb/IIIa inhibitor with the best track record to date in the setting of percutaneous coronary intervention (PCI), abciximab, was tested in UA/NSTEMI in the Global Use of Strategies To Open occluded coronary arteries in Acute Coronary Syndromes (GUSTO IV–ACS) trial, which enrolled patients in whom PCI was not intended, and showed no benefit.³ These disappointing results may have been related to issues of dosing, patient selection, and trial design, but nevertheless, they have led to a reappraisal of the utility of GP IIb/IIIa inhibitors in UA/NSTEMI.

See p 2767

In the present issue of Circulation, Roffi and colleagues⁴ revive enthusiasm for the use of GP IIb/IIIa inhibitors in acute coronary syndromes (ACS). They wished to determine whether patients presenting with UA/NSTEMI who had diabetes mellitus derived particular benefit from GP IIb/IIIa inhibition. To answer this question, they performed a meta-analysis of the 6 major, placebo-controlled, GP IIb/IIIa inhibitor trials to date. Stratifying by diabetic status, they found that assignment to active treatment with a GP IIb/IIIa inhibitor was associated with a significant 26% reduction in mortality among diabetic patients, whereas there was no effect among nondiabetics. These results were consistent across . . . [Full Text of this Article]

This article has been cited by other articles:

				S. D. Wiviott, E. Braunwald, S. A. Murphy, C. H. McCabe, E. M. Antman, D. J. Angiolillo, S. Meisel, A. J. Dalby, F. W.A. Verheugt, S. G. Goodman, et al. Response to Letter Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38" Circulation, June 30, 2009; 119(25): e602 - e603. [Full Text] [PDF]

				V. Fuster and M. E. Farkouh Acute Coronary Syndromes and Diabetes Mellitus: A Winning Ticket for Prasugrel Circulation, October 14, 2008; 118(16): 1607 - 1608. [Full Text] [PDF]

				S. D. Wiviott, E. Braunwald, D. J. Angiolillo, S. Meisel, A. J. Dalby, F. W.A. Verheugt, S. G. Goodman, R. Corbalan, D. A. Purdy, S. A. Murphy, et al. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation, October 14, 2008; 118(16): 1626 - 1636. [Abstract] [Full Text] [PDF]

				Diabetes mellitus and vascular risk: continuing the quest for the elusive keystone Diabetes and Vascular Disease Research, February 1, 2005; 2(1): 7 - 8. [PDF]

				R. A. Harrington, R. C. Becker, M. Ezekowitz, T. W. Meade, C. M. O'Connor, D. A. Vorchheimer, and G. H. Guyatt Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 513S - 548S. [Abstract] [Full Text] [PDF]

				M. Laakso and J. Kuusisto Diabetology for cardiologists Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B5 - B13. [Abstract] [PDF]

				Platelet GPIIb/IIIa Inhibitors Improve Survival in Diabetic ACS Patients Journal Watch Cardiology, February 8, 2002; 2002(208): 4 - 4. [Full Text]